By Stephen Nakrosis
Shares of Hoth Therapeutics were trading higher in Tuesday's pre-opening market, following news the company was granted a U.S. patent for its Alzheimer's treatment, HT-ALZ.
The company said it is preparing for clinical trials of HT-ALZ, with formulation currently under way.
Before the bell, the stock had risen 29% to trade at $1.06. Shares last closed above $1 on Sept. 18.
The stock finished Monday's regular session at 82 cents, rising 9% on the day.
The company said its treatment takes a novel approach by targeting the Substance P/Neurokinin-1 Receptor pathway, which is known to play a critical role in neuroinflammation, increasingly recognized as a driving factor in the progression of Alzheimer's disease.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 15, 2024 06:58 ET (10:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments